CAR-T Cells for the Treatment of Lung Cancer.
Life (Basel)
; 12(4)2022 Apr 08.
Article
in En
| MEDLINE
| ID: mdl-35455052
ABSTRACT
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies. However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses. The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy. Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Life (Basel)
Year:
2022
Document type:
Article
Affiliation country:
España